FIG 3.

Swimmers plot showing treatment response by depth and duration in relation to the chosen next line of therapy. Participants are defined as having received assay-guided therapy (blue bars) if they received one or more recommended drugs. The depth of response was measured using International Myeloma Working Group criteria. Shown to the right of the bars is the treatment received after HTS. D, dexamethasone; Dara, daratumumab; Doxil, liposomal doxorubicin; HTS, high-throughput screening; K, carfilzomib; PACE, cisplatin, doxorubicin, cyclophosphamide, and etoposide; Pano, panobinostat; PD, progressive disease; PR, partial response; R, lenalidomide; SD, stable disease; T, thalidomide; V, bortezomib; VGPR, very good partial response.